Natco Pharma's Canadian Unit, Celgene Sign Pact For Cancer Treatment Drug
Natco Pharma on Friday said its Canadian subsidiary has entered into a settlement agreement with biopharmaceutical firm Celgene (part of Bristol-Myers Squibb) for Lenalidomide capsules.
Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells.
"Natco Pharma (Canada) Inc., Canada, a subsidiary of Natco Pharma Ltd has entered into a settlement agreement with Celgene (now part of Bristol-Myers Squibb) for the product Lenalidomide Capsules in Canada," the company said in a regulatory filing.
The terms of the agreement are confidential as per the agreement, the company added.
Shares of Natco Pharma were trading 0.15 per cent lower at Rs 676.50 apiece on BSE.
HSBC Swings The Axe At UK Wealth In An AI Push
HSBC is preparing deep job cuts across its UK wealth management arm. It plans to cut about half of its management and sp... Read more
Kraken's Owner Buys A Bank: The Lines Are Blurring
Payward, the parent company of the crypto exchange Kraken, has agreed to buy a European bank. It would be the first digi... Read more
Revoluts Australian Banking Licence Game Changer
Revolut has spent much of its life insisting that it is more than a bank. In Australia, it has now decided that becoming... Read more
The AI Bank Is Coming, But Who Controls The Risk?
Artificial intelligence is no longer something banks discuss as a distant possibility. It is already working behind the ... Read more
ClearBank UK Profit Leads To European Growth
ClearBank has spent much of the past decade building the technology and regulatory infrastructure needed to challenge so... Read more
Bank Of London Continues To Rebuild
ClearBank’s progress shows that modern clearing and banking infrastructure can become a sizeable and profitable busine... Read more